Navigation Links
Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors
Date:8/24/2010

NEW YORK, Aug. 24 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDSTD), a clinical-stage biotechnology company, announced today that Dr. Joseph Rubinfeld, one of the four original founders of Amgen, Inc., has agreed to join the company's board of directors. Dr. Rubinfeld will be instrumental to assisting the company's commercialization efforts of PermaDerm™, Regenicin's proprietary autologous cultured skin substitute intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

In addition to his efforts in founding Amgen, Dr. Rubinfeld has a forty-year history in pharmaceutical and consumer product development.  His accomplishments include the creation of the multi-billion dollar antibiotic Amoxicillin as well as the first synthetic biodegradable detergent. He has obtained over 100 patents during his distinguished career.  

Commenting on his decision to join Regenicin, Dr. Rubinfeld stated, "With the recent acquisition of the rights to this revolutionary technology, Regenicin is in a position to be the only company in the world capable of quickly growing and grafting a person's own skin. This is a critical development for the multi-billion dollar treatment market for burns and other wounds that are currently dependent on cadaver and pig skin," said Dr. Rubinfeld.  "These methods often have high rejection rates compared to virtually no rejection issues when a person's own skin is being used for grafting. I look forward to helping the team at Regenicin navigate through the final hurdles toward commercialization of this life improving technology."  

Dr. Rubinfeld began his career as a research scientist with several pharmaceutical and consumer product companies including Schering Plough and Colgate Palmolive. He served for 12 years at Bristol Myers, where in addition to developing Amoxicillin and Chephadroxil, he was instrumental in licensing their original anti-cancer line of products, including Mitomycin, Etoposide, and Bleomycin. After co-founding Amgen in 1980 and serving as its chief of operations, Dr. Rubinfeld has served as an advisor or Board member to a number of companies including AVI BioPharma and Quark Pharmaceuticals. In 1991 he co-founded Supergen, a drug development company based in Dublin, California, where he served as President and CEO until 2003 and as a member of the Board of Directors until 2005.  During that time he oversaw the company's initial public offering and its rise to a multi-billion dollar market capitalization. Management believes his wealth of experience in biotech and big pharma will be instrumental for Regenicin as it transitions to commercialization.

"We are honored to have Dr. Rubinfeld join our board," said Randall McCoy, Chief Executive Officer, Regenicin. "His expertise in regulatory product approval processes and subsequent commercialization will prove invaluable to Regenicin as we enter this new phase in our company's history and bring PermaDerm™ to patients worldwide."

About Regenicin, Inc.

Regenicin, Inc. is a clinical-stage company developing next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. Regenicin is a publicly traded company, with headquarters in New York, NY. Additional information can be found on the company's website, http://www.regenicin.com and in the company's filings with the Securities and Exchange Commission located at www.sec.gov.


'/>"/>
SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer
2. Protectus Medical Devices Appoints as Medical Director a Physician Surgeon With 20-Year Involvement in Senior Level Monitoring of Pharmaceutical and Medical Devices
3. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
4. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
5. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
6. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
7. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
8. Elsevier Appoints Top Diabetes and Endocrinology Researchers as Editors
9. Elsevier Appoints Martin OMalley as Managing Director of New Global Sales Group in Science & Technology Division
10. Avrio Appoints David L. Gelber to Director of Manufacturing
11. Accuray Appoints Peter Fine to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 28, 2017 Persistence Market Research in ... Debridement Product Market 2016-2024," offers insights into developments ... North America that are significantly ... the overall market performance has been taken into ... focuses on developing different products to retain market ...
(Date:2/28/2017)... , Feb. 28, 2017 The global gynecology ... by 2021 from USD 1.73 billion in 2016, at a ... ... report: http://www.reportlinker.com/p04734938-summary/view-report.html Major factors contributing to the ... gynecological diseases, increasing awareness on gynecological diseases, and rising government ...
(Date:2/28/2017)... Summary ... This report provides all the information you require ... activities since 2010. Read the full report: http://www.reportlinker.com/p03605620-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
Breaking Medicine Technology:
(Date:3/1/2017)... , ... March 01, 2017 , ... After a long ... a spring cleanse. While juice cleanses and workouts top the detox categories, there is ... or physical regime. The Kerry Gaynor Method’s Vital Lung Detox is an herbal-based formula ...
(Date:3/1/2017)... , ... March 01, 2017 , ... ... PurThread’s permanently embedded anti-odor solution to cotton knit and woven fabrics. , ... while maintaining the luxurious look and feel of cotton. Cotton Incorporated has ...
(Date:3/1/2017)... ... , ... Award-winning medical group Allied Anesthesia today announced that, as of 2016, ... more than one trip per year since 1998. Char was named the Los Angeles ... details of his charitable work. Char has been an Allied Anesthesiologist since 2000. , ...
(Date:3/1/2017)... , ... March 01, 2017 , ... ... announced special pricing in the month of March for treatments aimed at tightening ... special features use on Thermage skin tightening, with 30 percent off all Thermage ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... “Letter of ... of published author, Maria Teresa Hamilton, survivor of the Civil War in El Salvador, ... Christian at the age of fifteen. I dedicated myself to serve in very poor ...
Breaking Medicine News(10 mins):